2. World Health Organization. Hepatitis B Fact Sheet. http://www.who. int/mediacentre/factsheets/fs204/en/

3. EASL 2017. Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017; 67: 370–98. https://doi.org/10.1016/ j.jhep.2017.03.021

4. Жданов К.В., Лобзин Ю.В., Гусев Д.А., Козлов К.В. Вирусные гепатиты. СПб: Фолиант, 2011. 304 с.

Zhdanov K.V., Lobzin Yu.V., Gusev D.A., Kozlov K.V. [Viral hepatitis]. Saint-Petersburg: Folio, 2011. 304 p. (In Russ.).

5. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167–85.

6. Schweitzer A., Horn J., Mikolajczyk R.T., Krause G., Ott J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546–55.

7. Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 288 с.

Abdurakhmanov D.T. [Сhronic hepatitis В and D]. Мoscow: GEOTAR-Media, 2010. 288 р. (In Russ.).

8. Baumert T.F., Thimme R., von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J. Gastroenterol. 2007; 13: 82–90. https://doi.org/ 10.3748/wjg.v13.i1.82

9. Balmasova I.P., Yushchuk N.D., Mynbayev O.A., Alla N.R., Malova E.S., Shi Z., Gao K.I. [Immunopathogenesis of chronic hepatitis B]. World J. Gastroenterol. 2014; 20 (39): 14156–71. doi: 10.3748/wjg.v20.i39.14156

10. Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol. Commun. 2018; 3(1): 8–19. doi:10.1002/hep4.1281

11. Seeger C., Mason W.S. Molecular biology of hepatitis B virus infection J. Virol. 2015; 479–480: 672–86. https://doi.org/10.1016/j.virol.2015.02.031

12. Lee J., Shin M.K., Lee H.J., Yoon G., Ryu W.S. Three novel cis-acting elements required for efficient plus-strand DNA synthesis of the hepatitis B virus genome. J. Virol. 2004; 78: 7455–64. doi: 10.1128/JVI.78.14.7455-7464.2004

13. Bertoletti A., Kennedy P.T. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol. Immunol. 2015; 12(3): 258–63. doi: 10.1038/cmi.2014.79

14. Said Z.N. An overview of occult hepatitis B virus infection. World. J. Gastroenterol. 2011; 17(15): 1927–38. doi: 10.3748/wjg.v17.i15.1927.

15. Wong D.K., Huang F.Y., Lai C.L., Poon R.T, Seto W.K., Fung J. et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829–36. doi: 10.1002/hep.24551

16. Roseman A.M., Borschukova O., Berriman J.A., Wynne S.A., Pumpens P., Crowther R.A. Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J. Mol. Biol. 2012; 423(1): 63–78. doi: 10.1016/j.jmb.2012.06.032.

17. Block T.M., Mehta A.S., Blumberg B.S., Dwek R.A. Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity? DNA Cell Biol. 2006; 25 (3):165–70. doi: 10,1089/dna.2006.25.165

18. Li L., Liu M., Cheng L.W., Gao X.Y., Fu J.J., Kong G. et al. HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. Scand. J. Immunol. 2013; 78(5): 439–46. doi: 10.1111/sji.12099

19. Buchmann P., Dembek C., Kuklick L., Jäger C., Tedjokusumo R., von Freyend M.J. et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31(8):1197–203. doi: 10.1016/ j.vaccine.2012.12.074

20. You J., Sriplung H., Geater A., Chongsuvivatwong V., Zhuang L., Chen H.Y. et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol. 2008; 14(7): 1112–9. doi: 10.3748/wjg.14.1112

21. Block T.M., Guo H., Guo J.T. Molecular virology of hepatitis B virus for clinicians. Clin. Liver Dis. 2007; 11(4): 685–706. doi: 10.1016/j.cld.2007.08.002

22. Shi Y.H., Shi C.H. Molecular characteristics and stages of chronic hepatitis B virus infection. World J. Gastroenterol. 2009; 15(25): 3099–105. doi: 10.3748/wjg.15.3099

23. Li N., Li Q., Qian Z., Zhang Y., Chen M., Shi G. Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. Biochem. Biophys. Res. Commun. 2009; 390(3):.630–5. doi: 10.1016/j.bbrc.2009.10.018

24. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008; 214(2): 199–210. doi: 10,1002/path.2277

25. Shi F., Zhang J.Y, Zeng Z., Tien P., Wang F.S. Skewed ratios between CD3(+) T cells and monocytes are associated with poor prognosis in patients with HBV-related acute-on-chronic liver failure. Biochem. Biophys. Res. Commun. 2010; 402(1): 30–6. doi: 10.1016/j.bbrc.2010.09.096

26. Feitelson M.A., Reis H.M.G.P.V., Liu J., Lian Z., Pan J. Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenezis. Frontiers in Bioscience 2005; 10: 1558–72. doi: 10,2741/1640

27. Zhang Z., Zhang J.Y., Wang L.F., Wang F.S. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 2012; 27(2): 223–30. doi: 10.1111/j.1440-1746. 2011.06940.x

28. Kim J.Y., Song E.H., Lee H.J., Oh Y.K., Choi K.H., Yu D.Y. et al. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J. Mol. Biol. 2010; 397(4): 917–31. doi: 10.1016/j.jmb.2010.02.016

29. Dunn C., Brunetto M., Reynolds G., Christophides T., Kennedy P.T., Lampertico P. et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 2007; 204(3): 667–80. doi: 10.1084/jem.20061287

30. Ratnam D., Visvanathan K. New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response. Hepatol. Int. 2008; 2(Suppl.1): 12–8. doi: 10.1007/s12072-008-9067-0

31. Chen J., Wu M., Zhang X., Zhang W., Zhang Z., Chen L. et al. Hepatitis B virus polymerase impairs interferon-α-induced STAT activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology 2013; 57(2): 470–82. doi: 10.1002/hep.26064

32. Ito T., Kanzler H., Duramad O., Cao W., Liu Y.J. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 2006; 107(6): 2423–31. DOI: 10,1182/кровь-2005-07-2709

33. Ma Y.J., He M., Han J.A., Yang L., Ji X.Y. A clinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B. Scand. J. Immunol. 2013; 78(4): 387–93. doi: 10.1111/sji.12097

34. Хохлова О.Н., Серебровская Л.В., Ходжибеков Р.Р., Гезахегне Д.Б., Кожевникова Г.М., Покровский В.В., Рейзис А.Р. Роль плазмоцитоидных дендритных клеток как новых иммуноцитов в патогенезе ХГС, ХГВ И ВИЧ-инфекции. Инфекционные болезни 2016; 14(4): 31–6.

Khokhlova O.N., Serebrovskaya L.V., Khodzhibekov R.R., Gezakhegne D.B., Kozhevnikova G.M., Pokrovskiy V.V., Reizis A.R. [The role of plasmacytoid dendritic cells as a new immune cells in the pathogenesis of chronic hepatitis C, chronic hepatitis B and HIV]. Infektsionnye bolezni 2016; 14(4): 31–6. (In Russ.).

35. Woltman A.M., Ter Borg M.J., Binda R.S., Sprengers D., von Blomberg B.M., Scheper R.J. et al. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir. Ther. 2009; 14(6): 809–18. doi: 10,3851/IMP1295

36. Sun H.H., Zhou D.F., Zhou J.Y. The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation. J. Med. Virol. 2016; 88: 13–20. doi:10.1002/jmv.24306

37. Duan X.Z., Wang M., Li H.W., Zhuang H., Xu D., Wang F.S. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J. Clin. Immunol. 2004; 24(6): 637–46. DOI: 10.1007/s10875-004-6249-y

38. Opden Brouw M.L., Binda R.S., van Roosmalen M.H., Protzer U., Janssen H.L., van der Molen R.G., Woltman A.M. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009; 126(2): 280–9. doi: 10.1111/j.1365-2567.2008.02896.x

39. Сепиашвили Р.И., Балмасова И.П., Кабанова Е.В., Малова Е.С., Славянская Т.А. Вирус гепатита В: биология, иммунопатогенез, система NK/NKT в вирусной персистенции. Журн. микробиол., эпидемиол., иммунол. 2006; (6): 76–83. PMID: 17163145

Sepiashvili R.I., Balmasova I.P., Kabanova E.V., Malova E.S., Slavianskaya TA. [Hepatitis B virus: biology, immunopathogenesis, NK/NKT system in viral persistence]. Zhurnal mikrobiologii, èpidemiologii i immunobiologii 2006; (6): 76–83. (In Russ.).

40. Lang K.S., Georgiev P., Recher M., Navarini A.A., Bergthaler A., Heikenwalder M. et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 2006; 116(9): 2456–63. DOI: 10,1172/JCI28349

41. Moretta A., Marcenaro E., Parolini S., Ferlazzo G., Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death. Differ. 2008; 15(2): 226–33. DOI: 10,1038/sj.cdd.4402170

42. Stoop J.N., Woltman A.M., Biesta P.J., Kusters J.G., Kuipers E.J., Janssen H.L., van der Molen R.G. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology 2007; 46(3): 699–705. DOI: 10.1002/hep.21761

43. Jinushi M., Takehara T., Tatsumi T., Yamaguchi S., Sakamori R., Hiramatsu N. et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4+CD25+ T cells with PD-1-dependent regulatory activities. Immunology 2007; 120(1): 73–82. DOI: 10,1111/j.1365-2567.2006.02479.x

44. Weng P.J., Ying H., Hong L.Z., Zhou W.H., Hu Y.R., Xu C.H. An analysis of CD3+CD56+ lymphocytes and their subsets in the peripheral blood of patients with chronic hepatitis B. Zhonghua Ganzangbing Zazhi 2008; 16(9): 654–6.

45. Rauch A., Laird R., McKinnon E., Telenti A., Furrer H., Weber R. et al. Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens 2007; 69 (Suppl 1): 237–40. DOI: 10,1111/j.1399-0039.2006.773_4.x

46. Peng G., Li S., Wu W., Sun Z., Chen Y., Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008; 123(1): 57–65. DOI: 10.1111/j.1365-2567.2007.02691.x

47. Zhang L., Zhao Y.. The regulation of Foxp3 expression in regulatory CD4(+) CD25(+) T cells: multiple pathways on the road. J. Cell Physiol. 2007; 211(3): 590–97. DOI: 10.1002/ jcp.21001

48. Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D. et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445(7130): 931–5. DOI: 10.1038/nature05478

49. Manigold T., Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect. Dis. 2007; 7(12): 804–13. DOI: 10.1016 / S1473-3099 (07)70289-X

50. Guo J.C., Bao J.F., Chen Q.W., Li X.O., Shi J.P., Lou G.Q. et al. Level of serum and liver tissue TGF-beta1 in patients with liver fibrosis due to chronic hepatitis B. Zhonghua Shiyan He Linchuangbingduxue Zazhi 2008; 22(5): 354–7.

51. Fallarino F., Grohmann U., You S., McGrath B.C., Cavener D.R., Vacca C. et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006; 176(11): 6752–61. DOI: 10.4049/ jimmunol.176.11.6752

52. Aalaei-Andabili S.H., Alavian S.M. Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis. Vaccine 2012; 30(38): 5595–602. doi: 10.1016/j.vaccine.2012.06.063

53. Feng I.C., Koay L.B., Sheu M.J., Kuo H.T., Sun C.S., Lee C. et al. HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. J. Biomed. Sci. 14(this issue), doi 10.1007/s11373-006-9129-z

54. Shimizu Y. T-cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World. J. Gastroenterol. 2012; 18(20): 2443–51. Doi: 10.3748/wjg.v18.i20.2443

55. Chen J., Wang X.M., Wu X.J., Wang Y., Zhao H., Shen B., Wang G.Q. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm. Res. 2011; 60(1): 47–53. doi: 10.1007/ s00011-010-0233-1

56. Nan X.P., Zhang Y., Yu H.T., Li Y., Sun R.L., Wang J.P., Bai X.F. Circulating CD4+CD25 high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. Viral Immunol. 2010; 23(1): 63–70. doi: 10.1089/vim.2009.0061

57. Zhang G.L., Xie D.Y., Lin B.L., Xie C., Ye Y.N., Peng L. et al. Imbalance of interleukin-17-producing CD4 T cells/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus-related acute-on-chronic liver failure. J. Gastroenterol. Hepatol. 2013; 28(3): 513–21. doi: 10.1111/jgh.12082

58. Kitani A., Xu L. Regulatory T cells and the induction of IL-17. Mucosal Immunol. 2008; 1(Suppl 1): S43–S46. doi: 10.1038/mi.2008.51

59. Zhang G.L., Xie D.Y., Ye Y.N., Lin C.S., Zhang X.H., Zheng Y.B. et al. High level of IL-27 positively correlated with Th17 cells may indicate liver injury in patients infected with HBV. Liver Int. 2014; 34(2): 266–73. doi: 10.1111 /liv.12268

60. Zerbini A., Pilli M., Boni C., Fisicaro P., Penna A., Di Vincenzo P. et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134(5): 1470–81. doi: 10.1053/j.gastro.2008.02.017